A man experienced severe health complications after losing 30 percent of his body weight in six months using tirzepatide, a new weight loss drug. Researchers at the University of Colorado reported the case in JAMA Internal Medicine. The 62-year-old, who had obesity, Type 1 diabetes, and hypothyroidism, was taking a weight-based dose of levothyroxine. After significant weight loss, he developed atrial fibrillation due to an excess of thyroid hormone.
It’s more of a general trend in multiple news articles and popculture in past few months. This one just finally set me off.
In this specific case it’s more about the headline than the rest of it.